CytomX Therapeutics Inc.
0.85
-0.04 (-4.21%)
At close: Jan 14, 2025, 3:59 PM
0.87
2.34%
Pre-market Jan 15, 2025, 08:04 AM EST

CytomX Therapeutics Statistics

Share Statistics

CytomX Therapeutics has 78.26M shares outstanding. The number of shares has increased by 15.56% in one year.

Shares Outstanding 78.26M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.18%
Owned by Institutions (%) n/a
Shares Floating 76.94M
Failed to Deliver (FTD) Shares 35.48K
FTD / Avg. Volume 2.77%

Short Selling Information

The latest short interest is 5.54M, so 7.08% of the outstanding shares have been sold short.

Short Interest 5.54M
Short % of Shares Out 7.08%
Short % of Float 7.2%
Short Ratio (days to cover) 3.52

Valuation Ratios

The PE ratio is -201.06 and the forward PE ratio is -1.79.

PE Ratio -201.06
Forward PE -1.79
PS Ratio 1.13
Forward PS 1.7
PB Ratio -2.41
P/FCF Ratio -2.01
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

CytomX Therapeutics Inc. has an Enterprise Value (EV) of 111.21M.

EV / Earnings -195.44
EV / Sales 1.1
EV / EBITDA -25.81
EV / EBIT -17.15
EV / FCF -1.96

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.

Current Ratio 1.17
Quick Ratio 1.17
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage 0

Financial Efficiency

Return on equity (ROE) is 0.01% and return on capital (ROIC) is -3.32%.

Return on Equity (ROE) 0.01%
Return on Assets (ROA) 0%
Return on Capital (ROIC) -3.32%
Revenue Per Employee 843.45K
Profits Per Employee -4.74K
Employee Count 120
Asset Turnover 0.5
Inventory Turnover 0

Taxes

Income Tax 3.89M
Effective Tax Rate 1.17

Stock Price Statistics

The stock price has increased by -49.1% in the last 52 weeks. The beta is 1.06, so CytomX Therapeutics 's price volatility has been higher than the market average.

Beta 1.06
52-Week Price Change -49.1%
50-Day Moving Average 1.05
200-Day Moving Average 1.43
Relative Strength Index (RSI) 33.35
Average Volume (20 Days) 1.28M

Income Statement

In the last 12 months, CytomX Therapeutics had revenue of 101.21M and earned -569.00K in profits. Earnings per share was -0.01.

Revenue 101.21M
Gross Profit 101.21M
Operating Income -6.48M
Net Income -569.00K
EBITDA -4.31M
EBIT -6.48M
Earnings Per Share (EPS) -0.01
Full Income Statement

Balance Sheet

The company has 17.17M in cash and 13.97M in debt, giving a net cash position of 3.20M.

Cash & Cash Equivalents 17.17M
Total Debt 13.97M
Net Cash 3.20M
Retained Earnings -723.45M
Total Assets 138.98M
Working Capital 4.95M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -56.03M and capital expenditures -840.00K, giving a free cash flow of -56.88M.

Operating Cash Flow -56.03M
Capital Expenditures -840.00K
Free Cash Flow -56.88M
FCF Per Share -0.77
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -6.41% and -0.56%.

Gross Margin 100%
Operating Margin -6.41%
Pretax Margin 3.28%
Profit Margin -0.56%
EBITDA Margin -4.26%
EBIT Margin -6.41%
FCF Margin -56.19%

Dividends & Yields

CTMX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -1.18%
FCF Yield -85.49%
Dividend Details

Analyst Forecast

The average price target for CTMX is $5.79, which is 581.2% higher than the current price. The consensus rating is "Hold".

Price Target $5.79
Price Target Difference 581.2%
Analyst Consensus Hold
Analyst Count 6
Stock Forecasts

Scores

Altman Z-Score -5.72
Piotroski F-Score 5